Why Naltrexone Has Been Used Internationally for Decades
People searching for a drug to reduce alcohol cravings are often surprised to discover that effective medications have existed for decades, are widely used internationally, and are supported by a substantial body of clinical research.
Yet despite this evidence, awareness of these treatments remains relatively low in the UK.
For many people, alcohol reduction has traditionally been framed as an issue of willpower, counselling or long-term therapy. While psychological support undoubtedly plays an important role for some individuals, it is increasingly recognised that medication can also be a valuable tool in helping people reduce their alcohol consumption.
One of the most extensively studied drugs in this area is naltrexone.
What Is Naltrexone?
Naltrexone is a prescription-only medication that has been used in alcohol-related treatment pathways for more than thirty years.
It works differently from older treatments such as disulfiram, which causes unpleasant symptoms if alcohol is consumed.
Instead, naltrexone acts on the brain’s reward pathways.
Alcohol consumption stimulates the release of naturally occurring opioid chemicals within the brain. These chemicals contribute to feelings of pleasure and reinforcement associated with drinking.
Naltrexone blocks specific opioid receptors, particularly the mu-opioid receptor.
Researchers believe this may reduce the rewarding effects associated with alcohol and may help some individuals:
- think about alcohol less frequently;
- stop drinking earlier;
- consume fewer drinks during a drinking occasion;
- reduce episodes of heavy drinking;
- regain a sense of control over alcohol consumption.
Does It Actually Work?
The simple answer is yes — for many people.
Unlike countless supplements, detox programmes and internet remedies, naltrexone has been evaluated in numerous randomised controlled clinical trials.
Studies have demonstrated reductions in:
- heavy drinking days;
- overall alcohol consumption;
- relapse rates;
- the frequency of binge drinking episodes.
One of the largest studies, the COMBINE Study, published in JAMA, found that naltrexone improved drinking outcomes when compared with placebo, particularly when combined with supportive interventions.
Meta-analyses have similarly concluded that naltrexone has a measurable effect in reducing alcohol consumption in selected patients.
Importantly, however, not everyone responds.
Some people experience substantial benefits.
Others notice more modest changes.
And unfortunately, there are individuals for whom the medication appears to have little effect.
This variation in response is seen across many areas of medicine.
Medication Versus Therapy
To be clear, this is not an argument against therapy.
Psychological interventions can be extremely helpful.
For some people, counselling, behavioural programmes or peer support provide exactly what they need.
However, therapy is not always accessible.
It can involve:
• waiting lists;
• significant expense;
• ongoing commitments;
• time away from work or family responsibilities.
Private counselling can easily cost:
£60–£150 per session
and a structured programme over several months may run into thousands of pounds.
Medication, by comparison, can often represent a more affordable intervention.
For many people, it is also easier to access and easier to incorporate into daily life.
Increasingly, clinicians recognise that treatment does not need to be an either-or decision.
Medication and behavioural support can complement one another.
But for some individuals, medication alone may still provide meaningful benefits.
Widely Used Internationally
Naltrexone is well established in several healthcare systems.
It is prescribed routinely across parts of:
- Europe;
- Scandinavia;
- the United States;
- Australia.
International clinical guidelines frequently recognise naltrexone as an evidence-based option for alcohol-related conditions.
This has led many patients to ask an understandable question:
If the medication is considered safe, has been studied extensively and is used widely elsewhere, why isn’t it prescribed more often in the UK?
There is probably no single answer.
Awareness remains relatively limited.
Alcohol treatment pathways in the UK have historically focused heavily on abstinence models and specialist services.
In addition, prescribing practices vary considerably between regions and healthcare settings.
Some patients report difficulty accessing continuation prescribing after discharge from NHS alcohol services.
Others are unaware that treatment options exist at all.
Safety Profile
Naltrexone has been used clinically for decades and generally has a well-characterised safety profile.
As with any prescription medicine, it is not suitable for everyone.
Individuals taking opioid medications, or those with certain medical conditions, may not be appropriate candidates.
Treatment should always be considered following assessment by a qualified prescribing clinician.
Looking Forward
The conversation around alcohol treatment is changing.
People increasingly want options that fit around modern life.
Not everyone wants complete abstinence.
Not everyone wants years of therapy.
Many people simply want to drink less, sleep better, spend less money and feel healthier.
For some individuals, a drug to reduce alcohol cravings may form part of that journey.
At www.drinklessmethod.co.uk, we recognise that everyone’s goals are different. Whether the aim is moderation, alcohol reduction or complete abstinence, treatment decisions should be personalised, evidence-informed and guided by appropriate clinical assessment.
References
Anton RF et al. Combined Pharmacotherapies and Behavioural Interventions for Alcohol Dependence (COMBINE Study). JAMA. 2006.
Ray LA et al. Naltrexone for the Treatment of Alcohol Use Disorders: Mechanisms and Clinical Application. CNS Drugs. 2010.
Sinclair JD. Evidence About the Use of Naltrexone in Alcohol Dependence. Alcohol and Alcoholism. 2001.
Important Information
Naltrexone is a prescription-only medicine and is not suitable for everyone. Treatment is only considered following clinical assessment and approval by a qualified prescribing clinician. Individual responses to treatment vary.